Altered T‐cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase‐4 inhibitor: A 1‐year open‐label randomized controlled trial

AIMS/INTRODUCTION: Dipeptidyl peptidase‐4 inhibitor has been proven to improve glycemic control and β‐cell function in latent autoimmune diabetes in adults (LADA). The potential immune modulation mechanism is still unknown. Thus, we tested T‐lymphocyte subsets and expression of relevant transcriptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xia, Yang, Lin, Cheng, Ying, Zheng, Peilin, Hu, Jingping, Huang, Gan, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400151/
https://www.ncbi.nlm.nih.gov/pubmed/29883070
http://dx.doi.org/10.1111/jdi.12873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400151/
https://www.ncbi.nlm.nih.gov/pubmed/29883070
http://dx.doi.org/10.1111/jdi.12873

Ejemplares similares